TIDMDDDD
4d Pharma PLC
01 September 2020
4D pharma plc
(the "Company" or "4D")
4D pharma hosts R&D webinar providing an overview of world
leading Live Biotherapeutic discovery platform, MicroRx(R)
Leeds, UK, 1 September, 2020 - 4D pharma plc, a pharmaceutical
company leading the development of Live Biotherapeutics, has today
made available its recorded R&D webinar discussing the science
behind their Live Biotherapeutic drug discovery engine,
MicroRx(R).
The event is introduced by Dr. Alex Stevenson, Chief Scientific
Officer, 4D pharma, and presented by Dr Imke Mulder, Research
Director, 4D pharma, alongside three senior members of her Research
team. The presentation provides detailed insights in to 4D's
MicroRx platform, followed by covering analysts participating in a
question and answer session.
Topics include:
-- Why 4D's focus on the mechanism of single-strain LBPs drives
a rational drug discovery approach and guides effective
development
-- How the MicroRx platform investigates functionality
-- The drug discovery process and considerations for the microbiome
-- 4D's proprietary culture collection
-- Neurodegenerative diseases and 4D pharma candidates - MRx0029 and MRx0005
-- MRx0518, oncology and the MicroRx platform
The presentation slides and recording of the event are
accessible via the "Reports and Presentations" area of 4D's website
at www.4dpharmaplc.com/en/investors/reports-presentations .
The microbiome is a novel area of medicine with profound impacts
on human health and disease. 4D pharma recently announced proof of
concept data for their lead immuno-oncology candidate MRx0518 in
combination with Keytruda, highlighting that the 42% disease
control rate observed in Part A of the study, far exceeded the
predefined 10% threshold for expansion. This, in addition with 4D
pharma holding the largest IP portfolio and working in diverse
therapy areas, has driven increased interest in the Company's
science and development from a range of stakeholders.
Dr Imke Mulder has led the multidisciplinary research group at
4D pharma since 2014, developing the MicroRx(R) platform and
discovering new Live Biotherapeutics. After completing her BSc and
MSc in Biology at Wageningen University in the Netherlands, she
moved to Aberdeen for her PhD, studying on the effects of dietary
components on the gut immune system. Imke then carried out 8 years
of post-doctoral work as a Research Fellow in the Gut Immunology
Group at the Rowett Institute of Nutrition and Health (RINH) in
Aberdeen. This work primarily focused on interactions between the
gut microbiota and the host immune system in different model
organisms.
An insightful Q&A session follows the presentation involving
analysts from Chardan, N+1 Singer, Bryan, Garnier & Co., Cantor
Fitzgerald, Jeffries, Jones Trading and
Ladenburg Thalmann & Co. No material new information is
provided in the webinar.
About 4D
Founded in February 2014, 4D pharma is a world leader in the
development of Live Biotherapeutics, a novel and emerging class of
drugs, defined by the FDA as biological products that contain a
live organism, such as a bacterium, that is applicable to the
prevention, treatment or cure of a disease. 4D has developed a
proprietary platform, MicroRx(R), that rationally identifies Live
Biotherapeutics based on a deep understanding of function and
mechanism.
4D's Live Biotherapeutic Products are orally delivered single
strains of bacteria that are naturally found in the healthy human
gut. The Company has six clinical studies in progress, namely a
Phase II clinical study of BLAUTIX(R) in Irritable Bowel Syndrome
(IBS), a Phase I/II study of MRx0518 in combination with KEYTRUDA
(pembrolizumab) in solid tumours, a Phase I study of MRx0518 in a
neoadjuvant setting for patients with solid tumours, a Phase I
study of MRx0518 in patients with pancreatic cancer, a Phase I/II
study of MRx-4DP0004 in asthma, and a Phase II study of MRx-4DP0004
in patients hospitalised with COVID-19. Preclinical-stage programs
include candidates for CNS disease such as Parkinson's disease and
other neurodegenerative conditions. The Company has a research
collaboration with MSD, a tradename of Merck & Co., Inc.,
Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics
for vaccines.
For more information, refer to https://www.4dpharmaplc.com .
Contact Information:
4D
Duncan Peyton, Chief Executive Officer +44 (0)113 895 0130
Investor Relations ir@4dpharmaplc.com
N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496
3000
Aubrey Powell / Justin McKeegan / Iqra Amin (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332
2500
Dominic Wilson / Phil Walker
Image Box Communications
Neil Hunter / Michelle Boxall +44 (0)20 8943 4685
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Private
Policy.
END
NRAEASNFESKEEFA
(END) Dow Jones Newswires
September 01, 2020 11:58 ET (15:58 GMT)
4d Pharma (LSE:DDDD)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
4d Pharma (LSE:DDDD)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
